Life Sciences Times, Author at Life Sciences Times

MassBio Pushes Back Against ‘Most Favored Nation’ Drug Pricing Policy Following Executive Order

May 14, 2025

Large Study Confirms Safety and Life-Saving Benefits of Contrast-Enhanced Ultrasound

May 14, 2025

Stylus Medicine Launches With $85M to Advance In Vivo Genetic Medicines and Next-Generation CAR-T Therapies

May 13, 2025

THIS WEEK'S STORIES

FDA Approves GE HealthCare’s Optison for Pediatric Use, Expanding Access to Enhanced Heart Imaging

May 13, 2025

AstraZeneca’s IMFINZI Shows Significant Benefit in Early Bladder Cancer, Phase III Trial Finds

May 9, 2025

BrightHeart Secures Third FDA Clearance and PCCP Approval, Advancing AI-Driven Prenatal Cardiac Imaging

May 14, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Mirvie Launches Encompass™, a First-of-Its-Kind Predictive Test for Preeclampsia, Marking a Shift Toward Personalized Prenatal Care

Michael Dowling to Step Down as Northwell Health CEO After 23 Years, John D’Angelo Named Successor

Median Technologies Files FDA Application for AI-Powered Lung Cancer Screening Software

Eight Sleep Launches Pod 5, the First AI-Powered Sleep System with Temperature Control, Elevation, Sound, and Real-Time Health Monitoring

EDITOR PICKS

MassBio Pushes Back Against ‘Most Favored Nation’ Drug Pricing Policy Following Executive Order

Large Study Confirms Safety and Life-Saving Benefits of Contrast-Enhanced Ultrasound

Stylus Medicine Launches With $85M to Advance In Vivo Genetic Medicines and Next-Generation CAR-T Therapies

THIS WEEK'S STORIES

FDA Approves GE HealthCare’s Optison for Pediatric Use, Expanding Access to Enhanced Heart Imaging

AstraZeneca’s IMFINZI Shows Significant Benefit in Early Bladder Cancer, Phase III Trial Finds

BrightHeart Secures Third FDA Clearance and PCCP Approval, Advancing AI-Driven Prenatal Cardiac Imaging

POPULAR CATEGORY

ABOUT US

FOLLOW US